Abstract | PURPOSE: METHODS: RESULTS: We accrued a total of 42 patients. CR rates ranged from 42.9% to 73.8% for the 7 days. The average CR rate for days 1 through 7 was 54%. Fourteen patients (33%) maintained a complete emetic response on each of the 7 days. The average CR rate for published studies in HSCT patients receiving an antiemetic regimen without aprepitant is 57%. Most common adverse effects reported by patients receiving aprepitant were hiccups (33%) and drowsiness (33%). CONCLUSIONS: The addition of aprepitant failed to meet our primary endpoint of increasing CR rates by 20%. The lower than expected CR rate was attributed to use of breakthrough antiemetics. Aprepitant did result in preventing emesis in the majority of patients and was associated with minimal side effects.
|
Authors | Betsy Paul, James A Trovato, Jennifer Thompson, Ashraf Z Badros, Olga Goloubeva |
Journal | Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
(J Oncol Pharm Pract)
Vol. 16
Issue 1
Pg. 45-51
(Mar 2010)
ISSN: 1477-092X [Electronic] England |
PMID | 19525301
(Publication Type: Clinical Trial, Journal Article)
|
Chemical References |
- Antiemetics
- Antineoplastic Agents
- Morpholines
- Serotonin Antagonists
- Aprepitant
- Dexamethasone
|
Topics |
- Antiemetics
(adverse effects, therapeutic use)
- Antineoplastic Agents
(administration & dosage, adverse effects)
- Aprepitant
- Dexamethasone
(adverse effects, therapeutic use)
- Drug Therapy, Combination
- Female
- Hematopoietic Stem Cell Transplantation
- Hiccup
- Humans
- Male
- Middle Aged
- Morpholines
(adverse effects, therapeutic use)
- Nausea
(chemically induced, drug therapy)
- Serotonin Antagonists
(adverse effects, therapeutic use)
- Severity of Illness Index
- Sleep Stages
- Time Factors
- Treatment Outcome
- Vomiting
(chemically induced, drug therapy)
|